Skip to main content

Table 2 PERCIST1.0 versus RECIST1.1 response

From: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma

Characteristic PERCIST1.0 response Total (n = 15)
CMR (n = 11) SMD (n = 2) PMD (n = 2)
RECIST1.1 response, n(%)
 CR 1 (9%) 0 0 1 (7%)
 PR 9 (82%) 2 (100%) 0 11 (73%)
 SD 1 (9%) 0 0 1 (7%)
 PD 0 0 2 (100%) 2 (13%)
  1. CMR complete metabolic response, CR complete response, PMD progressive metabolic disease, PMR partial metabolic response, PR partial response, SD stable disease, SMD stable metabolic disease